Literature DB >> 24667682

Biomanufacture of human platelets for transfusion: Rationale and approaches.

Eun-ju Lee1, Pankaj Godara1, David Haylock2.   

Abstract

Platelets for transfusion obtained from volunteer blood donors are a limited resource. Given the increased range of donor restrictions to prevent transmission of disease and the decline in volunteer blood donors, there is a diminishing supply of blood for transfusion. Production of mature blood cells from hematopoietic stem cells via large-scale manufacture is an alternative way of meeting transfusion demands. In this review, we provide a detailed outline of the challenges and opportunities for the biomanufacture of platelets. We describe the scale required for platelet biomanufacture to deliver sufficient cells for transfusion, provide a brief outline of the current understanding of megakaryopoiesis and thrombogenesis, and highlight how the current understanding impacts the design of culture systems and bioreactors for producing platelets. Crown
Copyright © 2014. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24667682     DOI: 10.1016/j.exphem.2014.02.002

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  9 in total

Review 1.  Understanding platelet generation from megakaryocytes: implications for in vitro-derived platelets.

Authors:  Xiuli Sim; Mortimer Poncz; Paul Gadue; Deborah L French
Journal:  Blood       Date:  2016-01-19       Impact factor: 22.113

Review 2.  Road blocks in making platelets for transfusion.

Authors:  J N Thon; D A Medvetz; S M Karlsson; J E Italiano
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

3.  Aryl hydrocarbon receptor-dependent enrichment of a megakaryocytic precursor with a high potential to produce proplatelets.

Authors:  Catherine Strassel; Nathalie Brouard; Lea Mallo; Nicolas Receveur; Pierre Mangin; Anita Eckly; Ivan Bieche; Karin Tarte; Christian Gachet; François Lanza
Journal:  Blood       Date:  2016-03-10       Impact factor: 22.113

4.  Identifying and enriching platelet-producing human stem cell-derived megakaryocytes using factor V uptake.

Authors:  Xiuli Sim; Danuta Jarocha; Vincent Hayes; Hayley A Hanby; Michael S Marks; Rodney M Camire; Deborah L French; Mortimer Poncz; Paul Gadue
Journal:  Blood       Date:  2017-04-28       Impact factor: 22.113

5.  Predictions for optimal mitigation of paracrine inhibitory signalling in haemopoietic stem cell cultures.

Authors:  Joseph D Berry; Pankaj Godara; Petar Liovic; David N Haylock
Journal:  Stem Cell Res Ther       Date:  2015-04-16       Impact factor: 6.832

Review 6.  Manipulating megakaryocytes to manufacture platelets ex vivo.

Authors:  P Karagiannis; K Eto
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

Review 7.  On the Way to in vitro Platelet Production.

Authors:  Catherine Strassel; Christian Gachet; François Lanza
Journal:  Front Med (Lausanne)       Date:  2018-08-28

Review 8.  [Cultured platelets].

Authors:  C Strassel; F Lanza; C Gachet
Journal:  Bull Acad Natl Med       Date:  2020-10-14       Impact factor: 0.144

Review 9.  [Novel platelet pharming using human induced pluripotent stem cells].

Authors:  C Flahou; N Sugimoto; K Eto
Journal:  Bull Acad Natl Med       Date:  2020-09-28       Impact factor: 0.144

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.